HCA Q3 2021 Earnings Report
Key Takeaways
HCA Healthcare reported a strong third quarter in 2021 with revenues of $15.276 billion and net income of $2.269 billion, driven by increased patient volumes and gains on sales of facilities, despite the challenges posed by the Delta variant.
Revenues increased to $15.276 billion, compared to $13.311 billion in Q3 2020.
Net income attributable to HCA Healthcare, Inc. was $2.269 billion, or $7.00 per diluted share, compared to $668 million, or $1.95 per diluted share, in Q3 2020.
Adjusted EBITDA totaled $3.224 billion, compared to $2.053 billion in Q3 2020.
Same facility admissions and equivalent admissions increased by 6.8% and 9.3%, respectively.
HCA
HCA
Forward Guidance
HCA Healthcare revised its 2021 guidance, projecting revenues between $58.7 to $59.3 billion and adjusted EBITDA between $12.50 to $12.80 billion.
Positive Outlook
- Revenue is expected to be between $58.7 to $59.3 billion.
- Adjusted EBITDA is projected to be $12.50 to $12.80 billion.
- Diluted EPS is anticipated to be between $17.20 to $17.80.
- Capital expenditures are estimated to be approximately $3.7 billion.
- The guidance reflects current expectations regarding the impact of the COVID-19 pandemic and related government legislation.
Challenges Ahead
- Guidance excludes the impact of items such as gains or losses on sales of facilities.
- Guidance excludes the impact of losses on retirement of debt.
- Guidance excludes the impact of legal claims costs.
- Guidance excludes the impact of impairment of long-lived assets.
- The Company's guidance is subject to a number of known and unknown uncertainties and risks.